JAK inhibition ameliorated experimental autoimmune encephalomyelitis by blocking GM-CSF-driven inflammatory signature of monocytes

[1]  Changsheng Du,et al.  Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis. , 2022, Journal of Visualized Experiments.

[2]  Qiang Xu,et al.  New opportunities and challenges of natural products research: When target identification meets single-cell multiomics , 2022, Acta pharmaceutica Sinica. B.

[3]  Yu Zhou,et al.  A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal , 2022, Science advances.

[4]  B. Becher,et al.  TH Cells and Cytokines in Encephalitogenic Disorders , 2022, Frontiers in Immunology.

[5]  C. Harrison,et al.  Current and future status of JAK inhibitors , 2021, The Lancet.

[6]  Qian Li,et al.  Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway , 2021, Frontiers in Immunology.

[7]  B. Baradaran,et al.  Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS). , 2021, Life sciences.

[8]  Wei He,et al.  Biological drug and drug delivery-mediated immunotherapy , 2020, Acta pharmaceutica Sinica. B.

[9]  M. Mack,et al.  Cold exposure protects from neuroinflammation through immunologic reprogramming , 2020, bioRxiv.

[10]  L. Boon,et al.  Interleukin-17A Serves a Priming Role in Autoimmunity by Recruiting IL-1β-Producing Myeloid Cells that Promote Pathogenic T Cells. , 2020, Immunity.

[11]  G. Cutter,et al.  Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing , 2019, Neurology.

[12]  T. Kvien,et al.  New-generation JAK inhibitors: how selective can they be? , 2018, The Lancet.

[13]  Clare Baecher-Allan,et al.  Multiple Sclerosis: Mechanisms and Immunotherapy , 2018, Neuron.

[14]  A. Fournier,et al.  IL-1β enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells , 2018, Proceedings of the National Academy of Sciences.

[15]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[16]  S. Richman,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies , 2017, The Lancet Neurology.

[17]  P. Henson,et al.  Monocyte differentiation and antigen-presenting functions , 2017, Nature Reviews Immunology.

[18]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[19]  D. Schwartz,et al.  JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects , 2017, Drugs.

[20]  S. Hunter.  Overview and diagnosis of multiple sclerosis. , 2016, The American journal of managed care.

[21]  B. Becher,et al.  GM-CSF in Neuroinflammation: Licensing Myeloid Cells for Tissue Damage. , 2015, Trends in immunology.

[22]  B. Becher,et al.  The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. , 2015, Immunity.

[23]  J. C. Love,et al.  Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis , 2015, Science Translational Medicine.

[24]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[25]  Fan Yang,et al.  STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation , 2014, Cell Research.

[26]  Hyun-Dong Chang,et al.  IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells , 2014, Science Translational Medicine.

[27]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[28]  C. Egwuagu,et al.  Therapeutic targeting of STAT pathways in CNS autoimmune diseases , 2013, JAK-STAT.

[29]  D. Arnold,et al.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.

[30]  R. Plenge,et al.  JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.

[31]  F. Rossi,et al.  Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool , 2011, Nature Neuroscience.

[32]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[33]  F. Safavi,et al.  The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.

[34]  Maria Papatriantafyllou.  Cytokines: GM-CSF in focus , 2011, Nature Reviews Immunology.

[35]  Irah L. King,et al.  GM-CSF–dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization , 2010, The Journal of experimental medicine.

[36]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[37]  R. Ransohoff.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. , 2009, Immunity.

[38]  A. Mildner,et al.  CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. , 2009, Brain : a journal of neurology.

[39]  J. Goverman.  Autoimmune T cell responses in the central nervous system , 2009, Nature Reviews Immunology.

[40]  Irah L. King,et al.  Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. , 2009, Blood.

[41]  D. Levy,et al.  IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways , 2007, Nature Immunology.

[42]  J. Goverman,et al.  Active induction of experimental allergic encephalomyelitis , 2006, Nature Protocols.

[43]  T. Morio,et al.  Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. , 2006, Immunity.

[44]  R. Ransohoff,et al.  The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). , 2003, Seminars in immunology.

[45]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[46]  J. Johnston,et al.  Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.

[47]  Jingwu Z. Zhang,et al.  Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. , 2010, Nature medicine.